Brilliant science does not guarantee commercial success. In pharmaceutical and life science industries, the gap between a breakthrough and a revenue-generating product is where most launches fail. Not because the research and development (R&D) was wrong, but because the strategy surrounding it was.
Vardan Ter-Antonyan, Head of R&D, Bioenhancement, at Mile High Labs, and a product pipeline and operations leader with over 20 years of experience across pharma, over-the-counter (OTC), and supplement industries, has launched dozens of science-driven products and helped companies achieve up to 67% revenue growth through strategic commercialization. “Too often companies fall in love with the science but forget the market,” Ter-Antonyan says. “If your innovation does not have a route to market, it is just a prototype.”
Start With the End in Mind
Most product development cycles begin with the science and work toward the market. Ter-Antonyan inverts that sequence deliberately. The strategic roadmap for a next-generation launch begins with customer demand, regulatory pathways, and commercialization goals, before R&D investment deepens beyond the point where course correction is financially viable.
At Green Compass, the team focused exclusively on products with clear customer pull and a defined path to scale, which produced 50% revenue growth in a single year. Products that did not meet that filter were not included in the roadmap, regardless of scientific merit. That restraint created the result. Organizations that allow scientific enthusiasm to drive investment decisions without commercial validation build pipelines that impress internally and underperform in the market. The roadmap that drives revenue growth asks the commercial question first, not last.
Build a Cross-Functional Launch Engine
Isolated execution is when strategically sound launch plans fail operationally. Regulatory, quality, operations, and marketing pursue independent workstreams, converge at launch, and discover that decisions made in isolation are incompatible with the plan that the organization believed it was executing. The cost in time, capital, and market opportunity is significant and entirely preventable.
“Regulatory, quality, operations, and marketing; they all need to co-own the plan from day one,” Ter-Antonyan says. At Mile High Labs, for example, building an integrated product launch framework – that combined R&D and operations strategy from the outset – produced a 75% reduction in production costs alongside an accelerated time to market.
That result did not come from better individual function performance. It came from eliminating friction between functions optimizing for their own metrics rather than a shared outcome. “Success is not about departments,” he says. “It is about alignment.” Organizations that align at the start of a program do not spend the second half reconciling decisions made in silos.
Treat the Roadmap as a Living System
A roadmap built for conditions that existed at the start of a development cycle is a record of assumptions, not a launch strategy. Markets shift, regulatory environments evolve, and competitive dynamics change. The product differentiated months ago may be entering a crowded market by go-live. Organizations that discover this at launch have no mechanism to respond, but organizations that anticipated it do.
“Your launch roadmap has to adapt in real time,” Ter-Antonyan says. Working with CEOs stress-testing product pipelines against real-world volatility, he builds decision points, risk triggers, and performance checkpoints directly into the roadmap architecture. The goal is to make pivots planned rather than panicked. In high-investment, high-stakes launch environments, the difference between a strategic pivot and a crisis response is whether the organization designed for change or was simply surprised by it.
From Science to Commercial Scale
Organizations that convert scientific innovation into revenue align science with market reality before the investment is committed. They build cross-functional infrastructure that eliminates execution friction, and they design roadmaps that adapt when the market does not behave as anticipated. “With a strategic, cross-functional, and adaptive roadmap, you can turn scientific innovation into commercial success,” Ter-Antonyan says. The science creates the opportunity. The roadmap determines whether that opportunity reaches the market and what it delivers when it does.
Follow Vardan Ter-Antonyan on LinkedIn or visit Mile High Labs for more insights on product pipeline strategy, pharma commercialization, and science-led business growth.
